Anika Therapeutics (ANIK) Short-term Investments (2014 - 2026)

Anika Therapeutics (ANIK) has 13 years of Short-term Investments data on file, last reported at $25.8 million in Q1 2026.

• Short-term Investments for Q1 2026 came in at $25.8 million, up 17.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.8 million (up 17.2% YoY), and the FY2025 annual result was $23.7 million, changed 0.41% from the prior year.
• Short-term Investments rose to $25.8 million in Q1 2026 per ANIK's latest filing, from $23.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $36.7 million in Q2 2023 and troughed at $22.0 million in Q1 2025.
• A 5-year average of $29.1 million and a median of $29.3 million in 2022 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2025 and 2026: Short-term Investments sank 31.46% in 2025, then climbed 17.2% in 2026.
• A 5-year view of Short-term Investments shows it stood at $34.6 million in 2022, then retreated by 23.87% to $26.4 million in 2023, then fell by 10.49% to $23.6 million in 2024, then advanced by 0.41% to $23.7 million in 2025, then climbed by 8.77% to $25.8 million in 2026.
• Business Quant data shows ANIK's Short-term Investments at $25.8 million in Q1 2026, $23.7 million in Q4 2025, and $22.2 million in Q3 2025.